APA

Viéitez J. M., Valladares M., Peláez I., de Sande González L., García-Foncillas J., García-López J. L., García-Girón C., Reboredo M., Bovio H. & Lacave A. J. (20120124). A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143). : Investigational new drugs.

Chicago

Viéitez José María, Valladares Manuel, Peláez Ignacio, de Sande González Luis, García-Foncillas Jesús, García-López José Luis, García-Girón Carlos, Reboredo Margarita, Bovio Humberto and Lacave Angel Jiménez. 20120124. A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143). : Investigational new drugs.

Harvard

Viéitez J. M., Valladares M., Peláez I., de Sande González L., García-Foncillas J., García-López J. L., García-Girón C., Reboredo M., Bovio H. and Lacave A. J. (20120124). A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143). : Investigational new drugs.

MLA

Viéitez José María, Valladares Manuel, Peláez Ignacio, de Sande González Luis, García-Foncillas Jesús, García-López José Luis, García-Girón Carlos, Reboredo Margarita, Bovio Humberto and Lacave Angel Jiménez. A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143). : Investigational new drugs. 20120124.